omniture
DAEWOONG PHARMACEUTICAL

Latest News

Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of t...

2025-10-27 19:00 975

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

* More than 80% relative bioavailability compared with injectable obesity therapy, well above the...

2025-08-13 15:36 1457

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technolog...

2025-06-11 12:00 2124

CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry

- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial i...

2025-04-24 00:00 2682

CG MedTech and CGBIO Showcase Korea's Spine Surgery Excellence to Global Experts

SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a lea...

2024-12-31 20:00 2762

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

- At "AMWC SEA 2024," one of the world's top three aesthetic medicine congresses, the Nabota booth ...

2024-12-05 16:33 2990

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae L...

2024-10-10 06:16 2817

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOsChang-Jae Lee and...

2024-07-29 20:00 2495

Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results

SEOUL, South Korea, May 14, 2024 /PRNewswire/ -- CGBio, a leading medical device company, announced...

2024-05-14 20:00 2492

Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA

SEOUL, South Korea, Nov. 28, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is pleased to announce th...

2023-11-28 08:00 2282

Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines

'Fexuprazan,' Novel drug for Gastroesophageal Reflux Disease, starts its release inthe Philippines....

2023-08-16 13:00 3130

Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs

– Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical tria...

2023-07-31 08:00 2994

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet

SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a S...

2023-07-19 08:52 2850

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is cu...

2023-05-26 06:00 2799

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

-  New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing er...

2023-05-19 20:00 2783

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

- Exclusive rights for the development and commercialization of DWP213388 in the global market to V...

2023-04-28 08:58 2577

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal

SEOUL, South Korea, April 24, 2023 /PRNewswire/ -- The research results of Daewoong Pharmaceutical'...

2023-04-24 14:53 3213

Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration

- 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to tar...

2023-04-18 17:16 3796

Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries

* Submitted an NDA to Indonesia, Philippines and Thailand * Signed the export contract in Brazil...

2023-03-22 21:20 3677

Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue

- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 bi...

2023-02-20 12:29 2431
123